Last $2.50 USD
Change Today +0.008 / 0.32%
Volume 6.8K
RXII On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
Frankfurt
As of 9:38 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Open
$2.50
Previous Close
$2.50
Day High
$2.50
Day Low
$2.49
52 Week High
02/24/14 - $6.84
52 Week Low
07/10/14 - $2.21
Market Cap
35.0M
Average Volume 10 Days
70.0K
EPS TTM
$-2.00
Shares Outstanding
14.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company’s lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

12 Employees
Last Reported Date: 03/28/14
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $368.1K
Chief Development Officer
Total Annual Compensation: $324.4K
Compensation as of Fiscal Year 2013.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Appoints Peter Campochiaro to Scientific Advisory Board

RXi Pharmaceuticals Corporation announced the appointment of Dr. Peter Campochiaro to its Scientific Advisory Board. Campochiaro is the George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience in the Johns Hopkins University School of Medicine. He is a prominent researcher, clinician and educator in the field of ophthalmology. He sees patients at the Wilmer Eye Institute at Johns Hopkins. With more than 300 articles published in peer-reviewed medical journals, Dr. Campochiaro is a clinician-scientist who does both laboratory and clinical research. His major laboratory interest is in elucidating the molecular pathogenesis of ocular neovascularization and excessive vascular leakage. He has generated many animal models of retinal and choroidal vascular diseases that have been useful for evaluating drug and gene-based therapies. His laboratory helped to demonstrate the importance of vascular endothelial growth factor (VEGF) in retinal and choroidal vascular diseases and his clinical trial group performed many of the early phase studies evaluating VEGF antagonists. He serves on Scientific Advisory Board of several pharmaceutical companies.

RXi Pharmaceuticals Corporation Announces the Opening of New Office and Laboratory in Marlborough Technology Center

RXi Pharmaceuticals Corporation announced the official opening of its new office and laboratory in the Marlborough Technology Center. The company will host a ribbon-cutting ceremony on July 9, 2014 at 257 Simarano Drive, Marlborough, MA, to mark the opening of their new facility. The ceremony will be held in collaboration with the Massachusetts Life Sciences Center (MLSC) and MassBio.

RXi Pharmaceuticals Approves Amendment to Certificate of Incorporation

RXi Pharmaceuticals announced at the Annual Meeting of Stockholders held on June 2, 2014, approved amendment to Certificate of Incorporation to reduce the number of shares of common stock authorized for issuance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $2.50 USD +0.008

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies
 

Industry Analysis

RXII

Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 83.8x
Price/Book 20.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit www.rxipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.